Scipio bioscience
Single-cell profiling for every benchtop
Scipio bioscience, a Paris-based biotechnology company,
provides a novel sample preparation solution
for single-cell studies, in the form of benchtop kits,
for use in sequencing applications
in clinical and basic research,
in particular transcriptomics.
13 November 2017
Scipio bioscience announces its seed fund raising
A total of €1.2m has been obtained from two European seed funds: Paris, France-based Seventure Partners' Quadrivium I seed fund and Bonn, Germany-based High-Tech Gründerfonds. Read the full press release here.
25 February 2020
Scipio bioscience announces its Series A fund raising
A total of €6.0m has been obtained from an international syndicate led by M Ventures (Amsterdam, The Netherlands), the corporate venture capital arm of Merck. The initial shareholders Seventure Partners' Quadrivum I (Paris, France) and High-Tech Gründerfonds (Bonn, Germany) participated in the capital increase, alongside additional investors Financière Arbevel (Paris, France) and Investiere Venture Capital (Zürich, Switzerland). Read the full press release here.
The team
Science enthusiasts, driven by a common vision:
develop, deliver... and enjoy it!
Prof Stuart Edelstein
President - Chief Scientific Officer
Stuart is a world-renowned biophysicist. A foreign associate of the French Academy of Science, his academic curriculum includes professorships at Cornell University (NY, USA), University of Geneva (Switzerland), ENS (Paris, France) and the Collège de France. Stuart also has start-up experience as co-founder
of a publicly listed biotech company.
(Since 2017)
Pierre Walrafen, PhD
Chief Executive Officer
An Ecole Polytechnique alumnus and qualified European Patent Attorney, Pierre's experience in biotech covers all stages of product development and includes, in addition to 10+ years of R&D, positions as alliance manager for a strategic industrial partnership in DNA-based diagnostics and as consultant for biotechnology clients in an IP firm.
(Since 2017)
Raya Poncin, PhD
R&D Project leader
Raya received her Ph.D. from the University of Toulouse III - Paul Sabatier, where she carried out research on biopolymers for tissue engineering and cell therapy applications.
She graduated previously from the Paris Institute of Bioengineering and obtained a Master's degree in polymer science from University Paris-Est Créteil.
(Since 2018)
Maël Le Bohec, PhD
R&D Project leader
Maël completed his PhD in polymer chemistry in 2017 at the IMMM (Le Mans Institute of Molecules and Materials). His research focused on the design, synthesis and characterization of functionalized polymers, and in particular of PEGylated cationic polymers for transfection. His experience includes teaching general, organic, and polymer Chemistry.
(Since 2018)
Jun Komatsu, PhD
Director of Innovation
Jun has 10+ years of experience in biotech R&D and is an expert in structural and functional analysis of DNA molecules for genetic testing and biomedical research. With a background in general engineering and industrial chemistry, he received his PhD on the subject of micromanipulation of biological molecules in an electrostatics laboratory of the Toyohashi University of Technology (Japan).
(Since 2018)
Stanislas Lipin
R&D Bioinformatician
Stanislas completed an M.S. in medical physics at Joseph Fourier University in Grenoble followed by an M.S. bioinformatics at Paris-Saclay University. He started his career at Lumex Instruments in Russia as research engineer for 3 years. He joined Scipio bioscience in 2018 as a bioinformatics engineer and focuses on single-cell RNA sequencing data analysis.
(Since 2018)
Antoine Graindorge, PhD
Senior R&D Project leader
Antoine has 16+ years of experience in RNA biology, investigating the role of RNA molecules in the regulation of gene expression. He obtained his PhD in Rennes where he studied the control of embryonic mRNAs expression. He pursued post-doctoral work focusing on post-transcriptional mRNA regulations at the CRG in Barcelona, and then on the roles and mechanisms of action of long noncoding RNAs at the Institut Curie, Paris.
(Since 2018)
Hélène Eckert
R&D Project leader
Hélène has over 10 years of experience in molecular biology. After receiving her M.S. in Plant Genetics from the University of Nebraska-Lincoln (USA), she worked on plant genetic engineering at Iowa State University (USA) and Bayer Crop Science (Lyon, France). She then joined the Curie Institute in Paris, where she spent 6 years studying long noncoding RNAs in vertebrate development.
(Since 2019)
Gwenaëlle Pasquero
Director of Business Development
Gwenaëlle has 16 years of experience in the Life Science industry. After graduating as a Life Scientist, she spent 5 years in development in the pharmaceutical industry, then worked as an operational sales manager. In 2009, she joined ABF to set up the tailor-made enzymes marketing strategy and operations. She also developed key accounts internationally, leading innovative projects from conception to launch.
(Since 2019)
Azadeh Saffarian, PhD
R&D Bioinformatics Project leader
Azadeh holds a PhD in Computer Science and Bioalgorithmics applied to RNA secondary structures prediction from the University Lille1 INRIA. She pursued 7 years of postdoctoral research at Inserm and Pasteur Institute in Paris. She developed her expertise in "omics" and the development of algorithms for HLA genes.
(Since 2019)
Anis Bouchnak
R&D Bioengineer
Anis is a bioengineer who recently graduated from Sup'biotech Paris in collaboration with Université Libre de Tunis. Passionate about science, he joined Scipio bioscience to work on the development of our new technologies.
(Since 2019)
Vivian Schindler
Office Manager
Vivian supervises our administrative projects and human resources, as well as accounting and general services. Polyglot and polyvalent, our team and partners benefit from her years of international experience. Skilled coordinator, she will respond to the inquiries of all our stakeholders.
(Since 2019)
Léa Cathaly
Assistant scientist
Léa is preparing a Professional degree in Pharmaceuticals, Cosmetics, and Health, with specialization in Biotechnologies, at the Higher Technical School of the Laboratory in Paris (ETSL). She joined Scipio bioscience as work-study assistant scientist and participates to the development of our kit.
(Since 2019)
Anaïs Vayaboury
Assistant Scientist
Anaïs is preparing a Biomedical Research degree at the School of Applied Biology of Paris (ESTBA). Currently intern at Scipio bioscience as assistant scientist, Anaïs contributes actively to our project by using both her theoretical and practical skills, as she discovers the start-up ecosystem.
(Since 2019)
Luc Walrafen
Chief Financial Officer
After graduating from ESSEC Business School, Luc worked, in France and Germany, for financial institutions and investment funds and then specialized in administering and advising start-ups at all stages of development in their structuration, business planning, fundraising and reporting.
(Since 2019)
Jörg Morf, PhD
R&D Advisor
A fellow of the Babraham Institute in Cambridge (UK), Jörg is pioneering research on the spatial organization of transcriptomes. His expertise includes the design and implementation of novel genome-wide sequencing applications, such as high-throughput molecular barcoding, and computational analyses.
(Since 2019)
Philippe Tramoy
Member of the Board
Philippe, a partner at Seventure Partners, is in charge of life siences investments for the Quadrivium I fund. He started his career as a Project Manager and Director of Business Development Europe in the Rhodia group and later founded a market and business intelligence company, CBDMT – Market & Business Intelligence, which he managed for 10 years prior to joining Seventure.
(Since 2017)
Arnaud Autret
Member of the Board
Arnaud is Investment Principal at M Ventures and based in Amsterdam. He received a PhD in immunology from the Pasteur Institute and a MSc in Finance from ESCP Europe. He started his career at KPMG as a Financial Auditor in the Healthcare business unit. He then worked at Seventure Partners as Senior Associate where he invested in Life Sciences companies.
(Since 2020)
Prof Stéphane Le Crom
Independent Member of the Board
Stéphane is the head of the Omics network of the Université Pierre et Marie Curie (UPMC, Paris, France) and of the genomics facility at the École normale supérieure (Paris). In addition to these positions, Stéphane teaches genomics at the UPMC, and heads a research team dedicated to data analysis from high-throughput genomics studies.
(Since 2017)
Frank Hensel, PhD
Board Observer
Frank is Senior Investment Manager at High-Tech Gründerfonds. He brings significant experience in biotechnology, as a scientist and founder of OncoMab GmbH, a spin-off of the University of Würzburg's Institute of Pathology. This expert in tumour-reactive antibodies focuses on the development of biologicals from the manufacturing phase to the clinical-trial stage.
(Since 2017)
Marc Le Bozec
Board Observer
Marc is Equity Portfolio Manager at Financière Arbevel since 2014. He graduated at HEC Business School and started his career at Bossard and Arthur D.Little, Organisation and Strategy Consulting Firms. Since more than 20 years, he developed his expertise in the biotechnologies field and held responsibilities as Executive Director and Entrepreneur at BioProtein, Alfact, Cellectis, CYTOO, Clevexel. Marc also served on the INSERM scientific committee between 2008 and 2016.
(Since 2020)
Ricardo Castro
Board Observer
Ricardo is an Investment Associate at
M Ventures and based in Amsterdam. Before joining M Ventures, Ricardo was working on his PhD degree from Swansea University in collaboration with the Nanomedicine department at the Houston Methodist Research Institute with a focus in nanotechnology and single-cell analysis. Ricardo graduated in Chemical Engineering and has worked as an external consultant and auditor for a broad scope of companies.
(Since 2020)

Team up!
We love to work with individuals of diverse backgrounds, who share our vision of a happy workplace.

Contact us if you enjoy generously sharing your skills and expertise to produce something useful, want to join a team where all are expected to contribute equally to a collaborative and fruitful environment... and are ready to work hard on challenges aimed at achieving an entrepreneurial success, where effort will be justly rewarded.

We are not searching for CVs, but for persons... So let us know who you are in addition to what you have done. See our contact below!
Why keep an eye on us
Scipio Bioscience exploits a proprietary technology that allows the preparation of samples for single-cell profiling. Based on a novel combination of established biochemical and biophysical approaches, the Scipio technology achieves
single-cell barcoding in a test tube format.
The Scipio solution provides unmatched flexibility regarding cell type or applications. All are addressed in an easy-to-use test tube format
Whether you are testing 10 samples per week or per year, you can use the Scipio solution in your own lab.
No large investment is involved, since no specific device is needed, and consumables are a fraction of the cost of current solutions.
Our partners
We work hard and believe in what we do...
but there's not much we could do without them
The ICM - Brain & Spine Institute is a unique research cluster, innovative in its design and its organisation, gathering patients, physicians and researchers in a single location to allow for faster development of cures for lesions of the nervous system.
The incubator of the Institut du Cerveau et de la Moelle Epinière, iPEPS-ICM, offers extensive services and a prime location in the unmatched research environment of Paris' largest hospital, La Pitié-Salpêtrière.
Seventure Partners
The Quadrivium I seed fund, managed by Seventure Partners, invests in early-stage companies with links to one of twelve major universities and academic institutions, in digital technologies and life sciences.
M Ventures
M Ventures is the strategic, corporate venture capital arm of Merck. M Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success.
High-Tech Gründerfonds
High-Tech Gründerfonds is Germany's most active seed stage investor, financing technology-driven companies in a wide range of fields to take their ideas through prototyping and to market launch.
Financière Arbevel
Financière Arbevel is an entrepreneurial investment management company based in Paris. Financière Arbevel launched its first European private equity fund with a cross-over approach focused on the non-listed life-science universe, with the idea of accompanying a limited number of biotechnology start-ups in their development.
investiere is the leading European startup investment platform for qualified and institutional investors and focuses on European high-tech startups. The investiere community consists of more than 4,000 qualified private investors, family offices and pension funds.
Région Île-de-France
Scipio bioscience is supported by the Programme d'Investissements d'Avenir and the Région Île-de-France.
The Innov'up Leader PIA program is designed to support the development of global leaders on their market.
Contact us
We are located at the Institut du Cerveau et de la Moelle épinière
47 boulevard de l'hôpital
75013 Paris

Phone: +33 157 274 115

Email any of us at, if you are not a robot and replace firstname and lastname with our names.
Made on